Literature DB >> 25788179

Characteristics and outcome of autoimmune liver disease in Asian children.

Way S Lee1, Su H Lum, Chooi B Lim, Sze Y Chong, Kim M Khoh, Ruey T Ng, Kai M Teo, Christopher C M Boey, Jayalakshmi Pailoor.   

Abstract

BACKGROUND: Little is known about autoimmune liver disease (AILD) in Asian children. We studied the clinical features and predictors of outcome in childhood AILD in an Asian population.
METHODS: Retrospective review of AILD [autoimmune hepatitis type 1 and 2 (AIH1, AIH2), primary sclerosing cholangitis (PSC) and autoimmune sclerosing cholangitis (ASC)] seen at two pediatric liver units in Malaysia.
RESULTS: At presentation, 17 (56%) of the 32 children [19 females, 59%; median (range) age 7.7 (1.8-15.5) years] with AILD (AIH1 = 18, AIH2 = 5, PSC = 0, ASC = 9) had liver cirrhosis. At final review [median (range) duration of follow-up 4.8 (0.4-12) years], 24 patients (75%) survived with a native liver. Twenty-one (66%) were in remission; 19 (AIH1 = 11; AIH2 = 4, ASC = 4) were on prednisolone and/or azathioprine, one on cyclosporine and another on mycophenolate mofetil. Three (AIH1 = 3) were in partial remission. Of the two who underwent liver transplantation (LT; 6.5%; both ASC), one died of primary graft failure after LT. Six patients (19%) died without LT (acute liver failure, n = 1; end-stage liver disease, n = 5). The overall survival rate (native liver and survival post-LT) was 78%. A delay in seeking treatment adversely affected the final outcome [survival with native liver vs. LT or death (duration between onset of disease and treatment; median ± standard error) = 2.5 ± 2.9 months vs. 24.0 ± 13.3 months; p = 0.012].
CONCLUSIONS: Although remission was achieved in the majority of patients with prednisolone and/or azathioprine therapy, delay in seeking diagnosis and treatment adversely affects the outcome of childhood AILD in Malaysia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25788179     DOI: 10.1007/s12072-014-9558-0

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  33 in total

1.  Diagnosis and management of autoimmune hepatitis.

Authors:  Michael P Manns; Albert J Czaja; James D Gorham; Edward L Krawitt; Giorgina Mieli-Vergani; Diego Vergani; John M Vierling
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

2.  The impact of race/ethnicity on the clinical epidemiology of autoimmune hepatitis.

Authors:  Robert John Wong; Robert Gish; Todd Frederick; Natalie Bzowej; Catherine Frenette
Journal:  J Clin Gastroenterol       Date:  2012-02       Impact factor: 3.062

3.  Natural history of active chronic hepatitis. I. Clinical features, course, diagnostic criteria, morbidity, mortality and survival.

Authors:  S P Mistilis; A P Skyring; C R Blackburn
Journal:  Australas Ann Med       Date:  1968-08

4.  International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.

Authors:  F Alvarez; P A Berg; F B Bianchi; L Bianchi; A K Burroughs; E L Cancado; R W Chapman; W G Cooksley; A J Czaja; V J Desmet; P T Donaldson; A L Eddleston; L Fainboim; J Heathcote; J C Homberg; J H Hoofnagle; S Kakumu; E L Krawitt; I R Mackay; R N MacSween; W C Maddrey; M P Manns; I G McFarlane; K H Meyer zum Büschenfelde; M Zeniya
Journal:  J Hepatol       Date:  1999-11       Impact factor: 25.083

5.  Outcome of biliary atresia in Malaysia: a single-centre study.

Authors:  Way-Seah Lee; Pei-Fan Chai; Kean-Seng Lim; Li-Han Lim; Lai-Meng Looi; Trndivanam Muthurangam Ramanujam
Journal:  J Paediatr Child Health       Date:  2009-05       Impact factor: 1.954

Review 6.  Autoimmune hepatitis: a comprehensive review.

Authors:  Rodrigo Liberal; Charlotte R Grant; Giorgina Mieli-Vergani; Diego Vergani
Journal:  J Autoimmun       Date:  2012-12-04       Impact factor: 7.094

7.  Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history.

Authors:  Mark Deneau; M Kyle Jensen; John Holmen; Marc S Williams; Linda S Book; Stephen L Guthery
Journal:  Hepatology       Date:  2013-08-13       Impact factor: 17.425

8.  High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.

Authors:  Keith D Lindor; Kris V Kowdley; Velimir A C Luketic; M Edwyn Harrison; Timothy McCashland; Alex S Befeler; Denise Harnois; Roberta Jorgensen; Jan Petz; Jill Keach; Jody Mooney; Carol Sargeant; Julie Braaten; Tamara Bernard; Debra King; Ellen Miceli; Jeff Schmoll; Tanya Hoskin; Prabin Thapa; Felicity Enders
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

9.  Autoimmune hepatitis in children--impact of cirrhosis at presentation on natural history and long-term outcome.

Authors:  Kadakkal R Radhakrishnan; Naim Alkhouri; Sarah Worley; Susana Arrigain; Vera Hupertz; Marsha Kay; Lisa Yerian; Robert Wyllie; Ariel E Feldstein
Journal:  Dig Liver Dis       Date:  2010-02-16       Impact factor: 4.088

Review 10.  Pathogenesis of autoimmune hepatitis.

Authors:  Rodrigo Liberal; Maria Serena Longhi; Giorgina Mieli-Vergani; Diego Vergani
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-12       Impact factor: 3.043

View more
  3 in total

1.  Autoimmune liver disease in Asian children.

Authors:  Giorgina Mieli-Vergani; Diego Vergani
Journal:  Hepatol Int       Date:  2015-01-06       Impact factor: 6.047

2.  Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis.

Authors:  Cumali Efe; Haider Al Taii; Henriette Ytting; Niklas Aehling; Rahima A Bhanji; Hannes Hagström; Tugrul Purnak; Luigi Muratori; Mårten Werner; Paolo Muratori; Daniel Klintman; Thomas D Schiano; Aldo J Montano-Loza; Thomas Berg; Fin Stolze Larsen; Naim Alkhouri; Ersan Ozaslan; Michael A Heneghan; Eric M Yoshida; Staffan Wahlin
Journal:  Dig Dis Sci       Date:  2018-03-22       Impact factor: 3.199

Review 3.  Autoimmune hepatitis: Standard treatment and systematic review of alternative treatments.

Authors:  Benedetta Terziroli Beretta-Piccoli; Giorgina Mieli-Vergani; Diego Vergani
Journal:  World J Gastroenterol       Date:  2017-09-07       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.